EBS Emergent Biosolutions Inc.

47.11
+1.39  (+3%)
Previous Close 45.72
Open 46.21
Price To Book 2.45
Market Cap 2,421,454,000
Shares 51,400,000
Volume 399,709
Short Ratio 7.23
Av. Daily Volume 484,157

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced September 9, 2017. Completion due 2019.
FLU-IGIV
Influenza A
Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 2b data likely due 2019.
IONIS-FXIRx
End-stage renal disease
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
VLA1601
Zika vaccine
Phase 3 trial planned for 2019.
NuThrax
Anthrax vaccine
Phase 2 interim analysis April 16, 2019.
CHIKV-VLP
Chikungunya virus

Latest News

  1. See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
  2. Before You Buy Emergent BioSolutions Inc. (NYSE:EBS), Consider Its Volatility
  3. Emergent BioSolutions CEO on fighting drug pricing and the opioid epidemic
  4. Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)
  5. Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
  6. Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
  7. What Emergent’s latest $535M contract means for national ‘smallpox franchise’
  8. Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
  9. Why Is Emergent Biosolutions (EBS) Down 23.4% Since Last Earnings Report?
  10. You Might Like Emergent BioSolutions Inc. (NYSE:EBS) But Do You Like Its Debt?
  11. Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe
  12. Emergent BioSolutions to Participate in Series of Investor Conferences
  13. Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
  14. 3 Top Healthcare Stocks to Buy in May
  15. Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
  16. Emergent BioSolutions Negotiates for a Strong Second Half